BACKGROUND/AIMS: The aim of the present study was to provide normative data and determine the validity of the Czech version of the Mattis Dementia Rating Scale 2 (czDRS-2) in screening for mild cognitive impairment in Parkinson's disease (PD-MCI) based on the Movement Disorder Society (MDS) Level II criteria. METHODS: For validation purposes, 41 healthy controls (HC), 46 patients with PD-NI (Parkinson's disease, no impairment) and 41 patients with PD-MCI (all groups assessed by the MDS Level II criteria for PD-MCI) were matched according to age and education. RESULTS: With screening and diagnostic cutoff scores determined at ≤139 points, the czDRS-2 showed a sensitivity of 78% and a specificity of 88% in the detection of PD-MCI versus HC and a sensitivity of 78% and a specificity of 76% in the detection of PD-MCI versus PD-NI. The AUC (95% confidence interval) for the czDRS-2 was 84% (75-93) and 82% (73-91), respectively. We report percentile values for 286 subjects from the Czech population stratified by education level. CONCLUSION: Our results show that the czDRS-2 is a valid instrument at Level I for screening PD-MCI and support its construct validity and diagnostic equivalence in a cross-cultural setting.
BACKGROUND/AIMS: The aim of the present study was to provide normative data and determine the validity of the Czech version of the Mattis Dementia Rating Scale 2 (czDRS-2) in screening for mild cognitive impairment in Parkinson's disease (PD-MCI) based on the Movement Disorder Society (MDS) Level II criteria. METHODS: For validation purposes, 41 healthy controls (HC), 46 patients with PD-NI (Parkinson's disease, no impairment) and 41 patients with PD-MCI (all groups assessed by the MDS Level II criteria for PD-MCI) were matched according to age and education. RESULTS: With screening and diagnostic cutoff scores determined at ≤139 points, the czDRS-2 showed a sensitivity of 78% and a specificity of 88% in the detection of PD-MCI versus HC and a sensitivity of 78% and a specificity of 76% in the detection of PD-MCI versus PD-NI. The AUC (95% confidence interval) for the czDRS-2 was 84% (75-93) and 82% (73-91), respectively. We report percentile values for 286 subjects from the Czech population stratified by education level. CONCLUSION: Our results show that the czDRS-2 is a valid instrument at Level I for screening PD-MCI and support its construct validity and diagnostic equivalence in a cross-cultural setting.
Authors: Taylor R Hendershott; Delphine Zhu; Seoni Llanes; Cyrus P Zabetian; Joseph Quinn; Karen L Edwards; James B Leverenz; Thomas Montine; Brenna Cholerton; Kathleen L Poston Journal: Mov Disord Date: 2018-12-10 Impact factor: 10.338
Authors: Francesca V Lopez; Lauren E Kenney; Adrianna Ratajska; Charles E Jacobson; Dawn Bowers Journal: Clin Neuropsychol Date: 2021-11-15 Impact factor: 4.373
Authors: Ondrej Bezdicek; Josef Mana; Filip Růžička; Filip Havlik; Anna Fečíková; Tereza Uhrová; Evžen Růžička; Dušan Urgošík; Robert Jech Journal: Front Aging Neurosci Date: 2022-06-17 Impact factor: 5.702
Authors: Ondrej Bezdicek; Tomas Nikolai; Jiri Michalec; Filip Růžička; Petra Havránková; Jan Roth; Robert Jech; Evžen Růžička Journal: Mov Disord Clin Pract Date: 2016-07-08
Authors: Danielle Pessoa Lima; Samuel Brito de Almeida; Janine de Carvalho Bonfadini; Emmanuelle Silva Tavares Sobreira; Patrícia Gomes Damasceno; Antonio Brazil Viana Júnior; Madeleine Sales de Alencar; João Rafael Gomes de Luna; Pedro Gustavo Barros Rodrigues; Isabelle de Sousa Pereira; André Luis de Castro Gadelha; Liliane Maria de Oliveira; Érica Carneiro Barbosa Chaves; Vlademir Gomes Carneiro; Rayane Rodrigues Monteiro; Thatyara Almeida de Macedo Costa; Lucas Helal; Joseph Signorile; Lidiane Andréa Oliveira Lima; Manoel Alves Sobreira-Neto; Pedro Braga-Neto Journal: BMJ Open Date: 2020-10-12 Impact factor: 2.692